Patent · US Active

Use of GABAA receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness

US10376524B2 · kind B2 · utility

0Cited by
4References
19Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 28, 2017
Grant dateAug 13, 2019
Priority date—
Expiry dateOct 13, 2037

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P25/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some embodiments, the GABAA receptor antagonist is flumazenil or clarithromycin. The GABAA receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narcolepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia), and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.